Trial Profile
A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2021
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 24 Jun 2021 Status changed from active, no longer recruiting to completed.
- 13 Dec 2019 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.
- 13 Dec 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2020.